A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10)

NCT04489888 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

101

Enrollment

INDUSTRY

Sponsor class

Conditions

Squamous Cell Carcinoma of Head and Neck

Interventions

DRUG: Pembrolizumab
DRUG: Carboplatin
DRUG: Paclitaxel

Sponsor

Merck Sharp & Dohme LLC